Biotech company MBX Biosciences saw a major specialist fund, MPM BioImpact, sell off its entire stake in the company, reducing exposure by an estimated $14.8 million. This move comes as MBX Biosciences gears up for pivotal trials, indicating a divergence in investor sentiment.
MPM BioImpact disclosed in a recent SEC filing that it sold its entire position in MBX Biosciences during the third quarter, eliminating its exposure and reducing reportable U.S. equity holdings by an estimated $14.8 million. Despite this, MBX shares have performed well, rising 71% over the past year and outperforming the S&P 500.
MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders, with promising lead candidates in its pipeline. The company has reported positive Phase 2 results for one of its drugs and completed a $200 million offering, positioning itself for future growth. Long-term investors should take note of these developments as MBX Biosciences accelerates towards key milestones.
